To evaluate the role of AIM1 on tumor growth and micrometastatic dissemination in vivo, we generated prostate cancer cell lines (VCaP and PC3) that stably overexpress either AIM1-targeting shRNAs (sh-AIM1) or non-targeting control shRNAs (sh-control) and established tumor xenogafts. This evidence concerns the gene CRYBG1 and prostate carcinoma.